These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36942976)

  • 1. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
    Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
    J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.
    Di Fusco M; Marczell K; Deger KA; Moran MM; Wiemken TL; Cane A; de Boisvilliers S; Yang J; Vaghela S; Roiz J
    J Med Econ; 2022; 25(1):605-617. PubMed ID: 35574613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States.
    Li R; Liu H; Fairley CK; Zou Z; Xie L; Li X; Shen M; Li Y; Zhang L
    Int J Infect Dis; 2022 Jun; 119():87-94. PubMed ID: 35338008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.
    Kohli MA; Maschio M; Joshi K; Lee A; Fust K; Beck E; Van de Velde N; Weinstein MC
    J Med Econ; 2023; 26(1):1532-1545. PubMed ID: 37961887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan.
    Nagano M; Kamei K; Matsuda H; Takahashi C; Yang J; Wada K; Yonemoto N
    Expert Rev Vaccines; 2024; 23(1):349-361. PubMed ID: 38411109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand.
    Thakkar K; Spinardi J; Kyaw MH; Yang J; Mendoza CF; Ozbilgili E; Dodd J; Yarnoff B; Punrin S
    Expert Rev Vaccines; 2023; 22(1):860-870. PubMed ID: 37779484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
    Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study.
    Andersson NW; Thiesson EM; Baum U; Pihlström N; Starrfelt J; Faksová K; Poukka E; Meijerink H; Ljung R; Hviid A
    BMJ; 2023 Jul; 382():e075286. PubMed ID: 37491022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
    Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
    Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Malaysia.
    Thakkar K; Spinardi J; Kyaw MH; Yang J; Mendoza CF; Dass M; Law W; Ozbilgili E; Yarnoff B
    Expert Rev Vaccines; 2023; 22(1):714-725. PubMed ID: 37548520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis.
    Nagano M; Tanabe K; Kamei K; Lim S; Nakamura H; Ito S
    Infect Dis Ther; 2024 Oct; 13(10):2155-2177. PubMed ID: 39254889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Kohli M; Maschio M; Becker D; Weinstein MC
    Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom.
    Harrison C; Butfield R; Yarnoff B; Yang J
    Expert Rev Vaccines; 2024; 23(1):730-739. PubMed ID: 39072472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
    Auvigne V; Tamandjou Tchuem CR; Schaeffer J; Vaux S; Parent Du Chatelet I
    Vaccine; 2023 Aug; 41(38):5490-5493. PubMed ID: 37541823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
    Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England.
    Kirsebom FCM; Andrews N; Stowe J; Dabrera G; Ramsay M; Lopez Bernal J
    EClinicalMedicine; 2024 May; 71():102587. PubMed ID: 38618208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.
    Mendes D; Chapman R; Gal P; Atwell J; Nguyen JL; Hamson L; Di Fusco M; Czudek C; Yang J
    J Med Econ; 2022; 25(1):1039-1050. PubMed ID: 36097853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan.
    Fust K; Joshi K; Beck E; Maschio M; Kohli M; Lee A; Hagiwara Y; Van de Velde N; Igarashi A
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.